2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1032

Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Abstract Number: 1033

Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis
Abstract Number: 1034

Microrna-146a Controls Local Bone Destruction By Regulating Fibroblast Induced Osteoclastogenesis in Inflammatory Arthritis
Abstract Number: 1035

The Prognostic Value of Different Auto-Antibodies for Arthritis Development in Patients with Clinically Suspect Arthralgia
Abstract Number: 1036

Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Abstract Number: 1037

Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort
Abstract Number: 1038

Functional Disability in Patients Presenting with Clinically Suspect Arthralgia and Progression to Clinical Arthritis
Abstract Number: 1039

Estimation of the Risk of Developing Rheumatoid Arthritis in High-Risk Subjects : Systematic Review and Meta-Analysis
Abstract Number: 1040

Stressful Life Events : A Trigger for Rheumatoid Arthritis Onset within a Year. a Case-Control Study
Abstract Number: 1041

Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
Abstract Number: 1042

Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1043

Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28
Abstract Number: 1044

Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis
Abstract Number: 1045

2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis
Abstract Number: 1046

Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].